Analytical technologies for influenza virus-like particle candidate vaccines: Challenges and emerging approaches

Virology Journal

Volumn 10, Issue , 2013, Pages

  Thompson, Christine M ^a,b   Petiot, Emma ^a   Lennaertz, Alexandre ^a,b   Henry, Olivier ^b   Kamen, Amine A ^a,b  

^a NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^b ÉCOLE POLYTECHNIQUE DE MONTRÉAL   (Canada)

Author keywords

Influenza virus like particles (VLPs); Process Analytical Technologies; Quantification; Total particles; Vaccines

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS LIKE PARTICLE VACCINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

CELL STRAIN HEK293; DNA VECTOR; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HELA CELL; IMMUNODIFFUSION; INFLUENZA VIRUS; INSECT CELL; PROTEIN ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; VERO CELL; VIRION; VIRUS HEMAGGLUTINATION; VIRUS STRAIN; WESTERN BLOTTING;

ORTHOMYXOVIRIDAE;

EID: 84876976274     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-141     Document Type: Review

References (80)

1. Monitoring influenza virus content in vaccine production: Precise assays for the quantitation of hemagglutination and neuraminidase activity. Kalbfuss B, Knöchlein A, Kröber T, Reichl U, Biologicals 2008 36 145 161 10.1016/j.biologicals.2007.10.002 18561375 (Pubitemid 351508423)
2. Influenza (Seasonal 2009) Factshee [ http://www.who.int/mediacentre/ factsheets/fs211/en/ ]
3. Out of Mexico ? Scientists Ponder Swine Flu' s Origins. Cohen J, Science 2009 324 700 703 10.1126/science.324-700 19423781
4. Novel swine-origin influenza A virus in humans: another pandemic knocking at the door. Michaelis M, Doerr HW, Cinatl J, Med Microbiol Immunol 2009 198 175 183 10.1007/s00430-009-0118-5 19543913
5. The annual production cycle for influenza vaccine. Gerdil C, Vaccine 2003 21 1776 1779 10.1016/S0264-410X(03)00071-9 12686093 (Pubitemid 36398372)
6. WHO, Department of Immunization, Vaccines and Biologicals Geneva: Global Pandemic Influenza Action Plan to Increase Vaccine Supply 2006
7. FDA News Release, FDA approves first seasonal influenza vaccine manufactured using cell culture technology 2012 http://www.fda.gov/newsevents/ newsroom/pressannouncements/ucm328982.htm
8. FDA News Release, FDA approves new seasonal influenza vaccine made using novel technology 2013 [ http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm335891.htm ]
9. Bench-to-bedside review: vaccine protection strategies during pandemic flu outbreaks. Chua JV, Chen WH, Critical Care (London, England) 2010 14 218 10.1186/cc8891
10. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. Kang S-M, Yoo D-G, Lipatov AS, Song J-M, Davis CT, Quan F-S, Chen L-M, Donis RO, Compans RW, PLoS One 2009 4 4667 10.1371/journal.pone. 0004667 19252744
11. Influenza virus-like particle vaccines. Haynes JR, Expet Rev Vaccine 2009 8 435 445 10.1586/erv.09.8
12. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. Wu C-Y, Yeh Y-C, Yang Y-C, Chou C, Liu M-T, Wu H-S, Chan J-T, Hsiao P-W, PLoS One 2010 5 9784 10.1371/journal.pone.0009784 20339535
13. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G, Vaccine 2005 23 5751 5759 10.1016/j.vaccine.2005.07.098 16143432 (Pubitemid 41668881)
14. Qualitative and quantitative analyses of virtually all subtypes of influenza A and B viral neuraminidases using antibodies targeting the universally conserved sequences. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Xu K, Lorbetskie B, Gingras G, Aubin Y, Van Domselaar G, Girard M, He R, Li X, Vaccine 2010 28 5774 5784 10.1016/j.vaccine.2010.06.075 20621113
15. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ, PLoS One 2011 6 26335 10.1371/journal.pone.0026335 22039464
16. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R, Mol Biotechnol 2010 45 226 234 10.1007/s12033-010-9268-3 20300881
17. Baculovirus-produced influenza virus-like particles in mammalian cells protect mice from lethal influenza challenge. Tang X-C, Lu H-R, Ross TM, Viral Immunol 2011 24 311 319 10.1089/vim.2011.0016 21830902
18. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. D'Aoust M-A, Couture MM-J, Charland N, Trépanier S, Landry N, Ors F, Vézina L-P, Plant Biotechnol J 2010 8 607 619 10.1111/j.1467-7652.2009.00496.x 20199612
19. Formation of Wild-Type and Chimeric Influenza Virus-Like Particles following Simultaneous Expression of Only Four Structural Proteins. Latham T, Galarza JM, Society 2001 75 6154 6165 (Pubitemid 32553146)
20. Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes. Pushko P, Pearce MB, Ahmad A, Tretyakova I, Smith G, Belser J, Tumpey TM, Vaccine 2011 29 5911 5918 10.1016/j.vaccine.2011.06.068 21723354
21. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. Quan F-S, Huang C, Compans RW, Kang S-M, J Virol 2007 81 3514 3524 10.1128/JVI.02052-06 17251294 (Pubitemid 46456660)
22. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Bright R, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM, Vaccine 2007 25 3871 3878 10.1016/j.vaccine.2007.01.106 17337102 (Pubitemid 46589748)
23. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Mahmood K, Bright R, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM, Vaccine 2008 26 5393 5399 10.1016/j.vaccine.2008.07.084 18706956
24. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. Lai JCC, Chan WWL, Kien FF, Nicholls JM, Peiris JSM, Garcia J-M, J Gen Virol 2010 91 Pt 9 2022 2030
25. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. Chen BJ, Leser GP, Morita E, Lamb R, J Virol 2007 81 7111 7123 10.1128/JVI.00361-07 17475660 (Pubitemid 46986647)
26. DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus. Szécsi J, Gabriel G, Edfeldt G, Michelet M, Klenk HD, Cosset F-L, J Infect Dis 2009 200 181 190 10.1086/599840 19505256
27. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Szécsi J, Boson B, Johnsson P, Dupeyrot-Lacas P, Matrosovich M, Klenk H-D, Klatzmann D, Volchkov V, Cosset F-L, Virol J 2006 3 70 10.1186/1743-422X-3- 70 16948862 (Pubitemid 44401678)
28. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP, Vaccine 2012 30 3413 3422 10.1016/j.vaccine.2012.03.033 22465746
29. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. D'Aoust M-A, Lavoie P-O, Couture MM-J, Trépanier S, Guay J-M, Dargis M, Mongrand S, Landry N, Ward BJ, Vézina L-P, Plant Biotechnol J 2008 6 930 940 10.1111/j.1467-7652.2008.00384.x 19076615
30. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. Wu C-Y, Yeh Y-C, Chan J-T, Yang Y-C, Yang J-R, Liu M-T, Wu H-S, Hsiao P-W, PLoS One 2012 7 42363 10.1371/journal.pone.0042363 22879951
31. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Quan FS, Steinhauer D, Huang C, Ross TM, Compans RW, Kang S-M, Vaccine 2008 26 3352 3361 10.1016/j.vaccine.2008.03.055 18468740
32. Protection against a Lethal Influenza Virus Challenge. Galarza JM, Latham T, Cupo A, Viral Immunol 2005 18 244 251 10.1089/vim.2005.18.244 15802970 (Pubitemid 40586463)
33. Influenza vaccines based on virus-like particles. Kang S-M, Song J-M, Quan F-S, Compans RW, Virus Res 2009 143 140 146 10.1016/j.virusres.2009.04.005 19374929
34. Counts of influenza virus particles. Donald HB, Isaacs A, J Gen Microbiol 1954 10 457 464 10.1099/00221287-10-3-457 13174769
35. Neuraminidase activity assays for monitoring MDCK cell culture derived influenza virus. Nayak DP, Reichl U, J Virol Meth 2004 122 9 15 10.1016/j.jviromet.2004.07.005 (Pubitemid 39370044)
36. A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines. Schild GC, Wood JM, Newman RW, Bull World Health Organ 1975 52 223 231 816480
37. The quantitative determination of influenza virus and antibodies by means of red cell agglutination. Hirst BYGK, J Exp Med 1942 75 49 64 10.1084/jem.75.1.49 19871167
38. Influenza: Propagation, Quantification and Storage. KJ S, Balish A, Katz J, Current Protocols in Microbiology John Wiley & Sons 2006 1 22
39. Simultaneous quantification of the viral antigens hemagglutinin and neuraminidase in influenza vaccines by LC-MSE. Creskey MC, Li C, Wang J, Girard M, Lorbetskie B, Gravel C, Farnsworth A, Li X, Smith DGS, Cyr TD, Vaccine 2012 30 4762 4770 10.1016/j.vaccine.2012.05.036 22643214
40. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, Donis RO, Barr JR, Vaccine 2008 26 2510 2520 10.1016/j.vaccine.2008.03.014 18440105
41. Optimization and qualification of a quantitative reversed-phase HPLC method for hemagglutinin in influenza preparations and its comparative evaluation with biochemical assays. Lorbetskie B, Wang J, Gravel C, Allen C, Walsh M, Rinfret A, Li X, Girard M, Vaccine 2011 29 3377 3389 10.1016/j.vaccine.2011.02.090 21397719
42. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Chun S, Li C, Van Domselaar G, Wang J, Farnsworth A, Cui X, Rode H, Cyr TD, He R, Li X, Vaccine 2008 26 6068 6076 10.1016/j.vaccine.2008.09.015 19007587
43. A novel assay for influenza virus quantification using surface plasmon resonance. Nilsson CE, Abbas S, Bennemo M, Larsson a, Hämäläinen MD, Frostell-Karlsson a, Vaccine 2010 28 759 766 10.1016/j.vaccine.2009.10.070 19857452
44. Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir. Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, Bethell RC, Anal Biochem 2000 280 291 300 10.1006/abio.2000.4517 10790313 (Pubitemid 30308085)
45. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Li C, Jaentschke B, Song Y, Wang J, Cyr TD, Van Domselaar G, He R, Li X, Nat Protoc 2010 5 14 19 10.1038/nprot.2009.200 20010723
46. One-step assay for detecting influenza virus using dynamic light scattering and gold nanoparticles. Driskell JD, Jones Ca, Tompkins SM, Tripp Ra, Analyst 2011 136 3083 3090 10.1039/c1an15303j 21666913
47. Comparing H1N1 Virus quantification with unique flow cytometer and quantitative PCR. Stepp PC, Ranno KA, Dawson ED, Rowlen KL, Ferris MM, Bioprocess I 2011 9 50 56
48. Improved particle counting and size distribution determination of aggregated virus populations by asymmetric flow field-flow fractionation and multiangle light scattering techniques. McEvoy M, Razinkov V, Wei Z, Casas-Finet JR, Tous GI, Schenerman M, Biotechnol Prog 2011 27 547 554 10.1002/btpr.499 21302365
49. Quantitative characterization of virus-like particles by asymmetrical flow field flow fractionation, electrospray differential mobility analysis, and transmission electron microscopy. Pease LF, Lipin DI, Tsai D-H, Zachariah MR, Lua LHL, Tarlov MJ, Middelberg APJ, Biotechnol Bioeng 2009 102 845 855 10.1002/bit.22085 18958863
50. Biophysical characterization of influenza virus subpopulations using field flow fractionation and multiangle light scattering: correlation of particle counts, size distribution and infectivity. Wei Z, McEvoy M, Razinkov V, Polozova A, Li E, Casas-Finet J, Tous GI, Balu P, Pan A, Mehta H, Schenerman M, J Virol Meth 2007 144 122 132 10.1016/j.jviromet.2007.04.008 (Pubitemid 47095043)
51. Release and stability testing programs for a novel virus-like particle vaccine. Pincus S, Boddapati S, Li J, Sadowski T, Pincus BS, Bio Pharm Int 2010 26 34
52. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina L-P, PLoS One 2010 5 15559 10.1371/journal.pone.0015559 21203523
53. HPLC-based quantification of haemagglutinin in the production of egg- and MDCK cell-derived influenza virus seasonal and pandemic vaccines. Kapteyn JC, Porre AM, De Rond EJP, Hessels WB, Tijms M, Kessen H, Slotboom AME, Oerlemans M, Smit D, Van der Linden J, Schoen P, Thus JLG, Vaccine 2009 27 1468 1477 10.1016/j.vaccine.2008.11.113 19110022
54. The influence of the host cell on standardisation of influenza vaccine potency. Wood J, Dunleavy U, Newman R, Riley A, Robertson J, Minor P, Dev Biol Stand 1999 98 183 188 10494972
55. An improved single-radial-immunodifusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. Wood J, Schild G, Newman R, Seagroatt V, J Biol Stand 1977 5 237 247 10.1016/S0092-1157(77)80008-5 408355 (Pubitemid 8143405)
56. Purification and concentration of influenza virus by auto-aggregation. Apostolov K, Fishman B, Nature 1967 1287 1288
57. Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. Petiot E, Jacob D, Lanthier S, Lohr V, Ansorge S, Kamen A, BMC Biotechnol 2011 11 84 10.1186/1472-6750-11-84 21884612
58. Purification of cell culture-derived human influenza A virus by size-exclusion and anion-exchange chromatography. Kalbfuss B, Wolff M, Morenweiser R, Reichl U, Biotechnol Bioeng 2007 96 932 944 10.1002/bit.21109 16937411 (Pubitemid 46479556)
59. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Wen Z, Ye L, Gao Y, Pan L, Dong K, Bu Z, Compans RW, Yang C, Antiviral Res 2009 84 215 224 10.1016/j.antiviral.2009.09. 005 19772876
60. Particle counts of haemagglutinating viruses. Isaacs A, Donald HB, J Gen Microbiol 1955 12 241 247 10.1099/00221287-12-2-241 14367748
61. Swine-origin pandemic H1N1 influenza virus-like particles produced in insect cells induce hemagglutination inhibiting antibodies in BALB/c mice. Krammer F, Nakowitsch S, Messner P, Palmberger D, Ferko B, Grabherr R, Biotechnol J 2010 5 17 23 10.1002/biot.200900267 20041443
62. Production of immunogenic one-component avian H7-subtype influenza virus-like particles. Chang GR-L, Lai S-Y, Chang P-C, Wang M-Y, Process Biochem 2011 46 1292 1298 10.1016/j.procbio.2011.02.019
63. Residual Baculovirus in Insect Cell-Derived Influenza Virus-Like Particle Preparations Enhances Immunogenicity. Margine I, Martinez-Gil L, Chou Y, Krammer F, PLoS One 2012 7 51559 10.1371/journal.pone.0051559 23236516
64. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza. Tang X-C, Lu H-R, Ross TM, Vaccine 2010 28 6821 6831 10.1016/j.vaccine.2010.08.040 20727393
65. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. Gavrilov V, Orekov T, Alabanza C, Porika U, Jiang H, Connolly K, Pincus S, J Virol Meth 2011 173 364 373 10.1016/j.jviromet.2011.03.011
66. Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: a novel RP-HPLC method. Kapteyn JC, Saidi MD, Dijkstra R, Kars C, Tjon JCMS-K, Weverling GJ, De Vocht ML, Kompier R, Van Montfort B, Guichoux J-Y, Goudsmit J, Lagerwerf FM, Vaccine 2006 24 3137 3144 10.1016/j.vaccine.2006.01.046 16490287
67. Rapid and selective characterization of influenza virus constituents in monovalent and multivalent preparations using non-porous reversed-phase high performance liquid chromatography columns. Garcia-Cañas V, Lorbetskie B, Girard M, J Chromatogr A 2006 1123 225 232 10.1016/j.chroma.2006.04.003 16677659 (Pubitemid 44150564)
68. Quantitative analyses of all influenza type A viral hemagglutinins and neuraminidases using universal antibodies in simple slot blot assays. Gravel C, Li C, Wang J, Hashem AM, Jaentschke B, Van Domselaar G, J Vis Exp 2011 50 1 7
69. GE Healthcare, Biacore ™ biosensor assays for quantitation of influenza virus and HCP Uppsala: GE Healthcare 2010 23674515
70. Monitoring of influenza virus hemagglutinin in process samples using weak affinity ligands and surface plasmon resonance. Mandenius C-F, Wang R, Aldén A, Bergström G, Thébault S, Lutsch C, Ohlson S, Anal Chim Acta 2008 623 66 75 10.1016/j.aca.2008.06.005 18611459
71. Design and characterization of a compact dual channel virus counter. Stoffel CL, Kathy RF, Rowlen KL, Cytometry Part A: J Int Soc Anal Cytol 2005 65 140 147 (Pubitemid 40726866)
72. Evaluation of the Virus counter for rapid baculovirus quantitation. Ferris MM, Stepp PC, Ranno KA, Mahmoud W, Jarvis J, Cox MMJ, Christensen K, Votaw H, Dean P, Rowlen KL, J Virol Meth 2012 171 111 116
73. A rapid label-free method for quantitation of human immunodeficiency virus type-1 particles by nanospectroscopy. Block O, Mitra A, Novotny L, Dykes C, J Virol Meth 2012 182 70 75 10.1016/j.jviromet.2012.03.012
74. Characterization of virus-like particle assembly for DNA delivery using asymmetrical flow field-flow fractionation and light scattering. Citkowicz A, Petry H, Harkins RN, Ast O, Cashion L, Goldmann C, Bringmann P, Plummer K, Larsen BR, Anal Biochem 2008 376 163 172 10.1016/j.ab.2008.02.011 18342613
75. Quantification of Viruses by Light Scattering. Saifer Mark GP, Williams DL, U.S Patent US6 2003 544 770 B2
76. Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Medley CD, Smith JE, Tang Z, Wu Y, Bamrungsap S, Tan W, Anal Chem 2008 80 1067 1072 10.1021/ac702037y 18198894 (Pubitemid 351272339)
77. Light-scattering signals from nanoparticles in biochemical assay, pharmaceutical analysis and biological imaging. Ling J, Huang CZ, Li YF, Zhang L, Chen LQ, Zhen SJ, TrAC Trends Anal Chem 2009 28 447 453 10.1016/j.trac.2009. 01.003
78. Dynamic light scattering as a powerful tool for gold nanoparticle bioconjugation and biomolecular binding studies. Jans H, Liu X, Austin L, Maes G, Huo Q, Anal Chem 2009 81 9425 9432 10.1021/ac901822w 19803497
79. Physical analysis of virus particles using electrospray differential mobility analysis. Pease LF, Trends Biotechnol 2012 30 216 224 10.1016/j.tibtech.2011.11.004 22172689
80. Evaluation of electrospray differential mobility analysis for virus particle analysis: potential applications for biomanufacturing. Guha S, Pease LF, Brorson K, Tarlov MJ, Zachariah MR, J Virol Meth 2011 178 201 208 10.1016/j.jviromet.2011.09.012